Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity

Research output: Contribution to journalReviewpeer-review

Standard

Cardiovascular effects of phentermine and topiramate : a new drug combination for the treatment of obesity. / Jordan, Jens; Astrup, Arne; Engeli, Stefan; Narkiewicz, Krzysztof; Day, Wesley W; Finer, Nick.

In: Journal of Hypertension, Vol. 32, No. 6, 2014, p. 1178-1188.

Research output: Contribution to journalReviewpeer-review

Harvard

Jordan, J, Astrup, A, Engeli, S, Narkiewicz, K, Day, WW & Finer, N 2014, 'Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity', Journal of Hypertension, vol. 32, no. 6, pp. 1178-1188. https://doi.org/10.1097/HJH.0000000000000145

APA

Jordan, J., Astrup, A., Engeli, S., Narkiewicz, K., Day, W. W., & Finer, N. (2014). Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. Journal of Hypertension, 32(6), 1178-1188. https://doi.org/10.1097/HJH.0000000000000145

Vancouver

Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. Journal of Hypertension. 2014;32(6):1178-1188. https://doi.org/10.1097/HJH.0000000000000145

Author

Jordan, Jens ; Astrup, Arne ; Engeli, Stefan ; Narkiewicz, Krzysztof ; Day, Wesley W ; Finer, Nick. / Cardiovascular effects of phentermine and topiramate : a new drug combination for the treatment of obesity. In: Journal of Hypertension. 2014 ; Vol. 32, No. 6. pp. 1178-1188.

Bibtex

@article{d1574faf1075401490aa795c2892a2da,
title = "Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity",
abstract = "Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.",
author = "Jens Jordan and Arne Astrup and Stefan Engeli and Krzysztof Narkiewicz and Day, {Wesley W} and Nick Finer",
note = "CURIS 2014 NEXS 100",
year = "2014",
doi = "10.1097/HJH.0000000000000145",
language = "English",
volume = "32",
pages = "1178--1188",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Cardiovascular effects of phentermine and topiramate

T2 - a new drug combination for the treatment of obesity

AU - Jordan, Jens

AU - Astrup, Arne

AU - Engeli, Stefan

AU - Narkiewicz, Krzysztof

AU - Day, Wesley W

AU - Finer, Nick

N1 - CURIS 2014 NEXS 100

PY - 2014

Y1 - 2014

N2 - Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.

AB - Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.

U2 - 10.1097/HJH.0000000000000145

DO - 10.1097/HJH.0000000000000145

M3 - Review

C2 - 24621808

VL - 32

SP - 1178

EP - 1188

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 6

ER -

ID: 105856192